Related Experiment Video
Updated: Aug 16, 2026

A Guide to Production, Crystallization, and Structure Determination of Human IKK1/α
Published on: November 2, 2018
Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity
1Division of Hematology/Oncology, Department of Medicine, Veterans Affairs Greater Los Angeles Healthcare System-West Los Angeles, CA 90073, USA.
Abstract:
Biallelic inactivating mutations of the von Hippel-Lindau tumor suppressor gene (VHL) are a hallmark of clear cell renal cell carcinoma (CCRCC), the most common histologic subtype of RCC. Biallelic VHL loss results in accumulation of hypoxia-inducible factor alpha (HIFalpha). Restoring expression of the wild-type protein encoded by VHL (pVHL) in tumors with biallelic VHL inactivation (VHL(-)(/)(-)) suppresses tumorigenesis, and pVHL-mediated degradation of HIFalpha is necessary and sufficient for VHL-mediated tumor suppression. The downstream targets of HIFalpha that promote renal carcinogenesis have not been completely elucidated. Recently, VHL loss was shown to activate nuclear factor kappa B (NF-kappaB), a family of transcription factors that promotes tumor growth. Here we show that VHL loss drives NF-kappaB activation by resulting in HIFalpha accumulation, which induces expression of transforming growth factor alpha, with consequent activation of an epidermal growth factor receptor/phosphatidylinositol-3-OH kinase/protein kinase B (AKT)/IkappaB-kinase alpha/NF-kappaB signaling cascade. We also show that components of this signaling pathway promote the growth of VHL(-)(/)(-) tumor cells. Members of this pathway represent viable drug targets in VHL(-)(/)(-) tumors, such as those associated with CCRCC.
Insights
Clear cell renal cell carcinoma (CCRCC) involves von Hippel-Lindau (VHL) gene mutations, leading to hypoxia-inducible factor alpha (HIFalpha) accumulation. This study reveals VHL loss activates nuclear factor kappa B (NF-kappaB) via HIFalpha, driving tumor growth and offering new therapeutic targets.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Biallelic inactivating mutations in the von Hippel-Lindau tumor suppressor gene (VHL) are characteristic of clear cell renal cell carcinoma (CCRCC).
- VHL gene inactivation leads to the accumulation of hypoxia-inducible factor alpha (HIFalpha).
- The precise downstream targets of HIFalpha driving renal carcinogenesis remain incompletely understood.
Purpose of the Study:
- To elucidate the downstream molecular mechanisms by which VHL loss promotes renal carcinogenesis.
- To investigate the role of hypoxia-inducible factor alpha (HIFalpha) and nuclear factor kappa B (NF-kappaB) signaling in VHL-deficient tumors.
- To identify potential therapeutic targets within the VHL-NF-kappaB pathway in CCRCC.
Main Methods:
- Analysis of VHL inactivation and its effect on HIFalpha accumulation.
- Investigating the induction of nuclear factor kappa B (NF-kappaB) signaling downstream of HIFalpha.
- Utilizing cell culture models to study the VHL-HIFalpha-NF-kappaB signaling cascade and its impact on tumor cell growth.
Main Results:
- VHL loss induces HIFalpha accumulation, which in turn activates nuclear factor kappa B (NF-kappaB).
- HIFalpha induces the expression of transforming growth factor alpha, initiating an EGFR/PI3K/AKT/IKKα/NF-kappaB signaling cascade.
- Components of this identified signaling pathway are crucial for the proliferation of VHL-deficient tumor cells.
Conclusions:
- VHL inactivation in CCRCC activates NF-kappaB signaling through HIFalpha accumulation.
- The identified EGFR/PI3K/AKT/IKKα/NF-kappaB pathway is a key driver of tumor growth in VHL-deficient renal cancer.
- Targeting components of this pathway presents a promising therapeutic strategy for VHL-mutated CCRCC.
Related Concept Videos
Co-activators and Co-repressors
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Regulation of Nuclear Protein Sorting
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein.
Abnormal Proliferation
